Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in Postmenopausal Women Undergoing Lumbar Spine Surgery
NCT06973109Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of romosozumab in osteoporosis (2 arms), sponsored by University of Pittsburgh. Primary endpoints: Change in Hounsfield Units at L1 Vertebra and Change in Vertebral Bone Mineral Density at L1. Planned start Jun 2026; status: withdrawn.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06973109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973109.